

MARKET REPORT



EpiCast Report: Heart Failure - Epidemiology Forecasts to 2026

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



EpiCast Report: Heart Failure - Epidemiology Forecasts to 2026

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

EpiCast Report: Heart Failure - Epidemiology Forecasts to 2026

EpiCast Report: Heart Failure - Epidemiology Forecasts to 2026

Summary

Heart failure (HF), also referred to as congestive cardiac failure, is a heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic needs of the body. Eventually, without the heart's pumping action to deliver oxygen and nutrient-rich blood to the cells, fatigue, shortness of breath, and coughing results. Even everyday activities such as walking, climbing stairs, or carrying weight can become tedious.

To forecast the diagnosed incident cases of HF and diagnosed prevalent cases of chronic HF (CHF) in the 7MM, GlobalData epidemiologists selected the best available nationally representative data ascertained through an exhaustive literature search.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of HF will increase from 1,990,569 cases in 2016 to 2,468,827 cases in 2026 at an annual growth rate (AGR) of 2.40%. The US had the highest number of diagnosed incident cases of HF in the 7MM in both 2016 and 2026, at 827,525 cases in 2016, and 1,081,878 cases in 2026.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of chronic HF (CHF) will increase from 14,403,423 cases in 2016 to 17,127,297 cases in 2026 at an AGR of 1.89%. The US had the highest number of diagnosed prevalent cases of CHF in the 7MM in both 2016 and 2026, at 5,816,242 cases in 2016, and 7,115,415 cases in 2026.

Scope

- The Heart Failure (HF) EpiCast Report provides an overview of the risk factors and global trends of HF in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of HF, diagnosed incident cases of HF segmented by ejection fraction and ventricular dysfunction, acute HF hospitalizations, acute HF hospitalizations by worsening HF, advanced HF, and de novo HF, and acute HF hospitalization by patients admitted and discharged, hospital length of stay for acute HF hospitalization, diagnosed prevalent cases of chronic HF (CHF), and diagnosed prevalent cases of CHF segmented by ejection fraction. The diagnosed prevalent cases of CHF, CHF with REF, and CHF with PEF are further classified according to the New York Heart Association (NYHA) functional classes I-IV. The diagnosed incident cases of HF and diagnosed prevalent cases of CHF are segmented by age (at 10-year intervals, for ages 45 years and older) and sex.

- The HF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Heart Failure EpiCast report will allow you to -

<https://www.bioportfolio.co.uk/product/105615>
reportstore@bioportfolio.com to order

- Develop business strategies by understanding the trends shaping and driving the global HF market.
- Quantify patient populations in the global HF market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HF therapeutics in each of the markets covered.
- Understand HF cases patient distribution by ejection fraction and NYHA functional classes.

Additional Details

Publisher : Global Data

Reference : GDHCER150-17

Number of Pages : 56

Report Format : PDF

Publisher Information :



GlobalData »

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for EpiCast Report: Heart Failure - Epidemiology Forecasts to 2026 [Report Updated: 12-06-2017]

- 1 Table of Contents1 Table of Contents 21.1 List of Tables 41.2 List of Figures 42 Heart Failure: Executive Summary 52.1 Related Reports 82.2 Upcoming Reports 83 Epidemiology 93.1 Disease Background 93.2 Risk Factors and Comorbidities 103.3 Global and Historical Trends 113.4 Forecast Methodology 133.4.1 Sources 143.4.2 Forecast Assumptions and Methods 223.4.3 Diagnosed Incident Cases of HF by EF 253.4.4 Diagnosed Incident Cases of HF by Ventricular Dysfunction 263.4.5 Acute HF Hospitalizations 273.4.6 Hospital Length of Stay for Acute HF Hospitalization 283.4.7 Diagnosed Prevalent Cases of CHF 293.4.8 Diagnosed Prevalent Cases of CHF by EF 313.4.9 Diagnosed Prevalent Cases of CHF by NYHA Classes 323.5 Epidemiological Forecast for Heart Failure (2016-2026) 343.5.1 Diagnosed Incident Cases of HF 343.5.2 Age-Specific Diagnosed Incident Cases of HF 353.5.3 Sex-Specific Diagnosed Incident Cases of HF 363.5.4 Diagnosed Incident Cases of HF by EF 373.5.5 Diagnosed Incident Cases of HF by VD 383.5.6 Acute HF Hospitalizations 383.5.7 Hospital Length of Stay for Acute HF Hospitalization 413.5.8 Diagnosed Prevalent Cases of CHF 413.5.9 Age-Specific Diagnosed Prevalent Cases of CHF 423.5.10 Sex-Specific Diagnosed Prevalent Cases of CHF 433.5.11 Diagnosed Prevalent Cases of CHF by EF 443.5.12 Diagnosed Prevalent Cases of CHF by NYHA Class 453.6 Discussion 473.6.1 Epidemiological Forecast Insight 473.6.2 Limitations of Analysis 483.6.3 Strengths of Analysis 484 Appendix 494.1 Bibliography 494.2 About the Authors 544.2.1 Epidemiologist 544.2.2 Reviewers 544.2.3 Global Director of Therapy Analysis and Epidemiology 554.2.4 Global Head and EVP of Healthcare Operations and Strategy 554.3 About GlobalData 564.4 Contact Us 564.5 Disclaimer 56

List Of Tables in EpiCast Report: Heart Failure - Epidemiology Forecasts to 2026 [Report Updated: 12-06-2017]

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for HF 10

Table 2: NYHA Functional Classification for CHF (Classes I-IV). 13

Table 3: 7MM, Diagnosed Incident Cases of HF, Both Sexes, Ages ≥ 45 Years, N, Selected Years 2016-2026 35

Table 4: 7MM, Diagnosed Prevalent Cases of CHF, Both Sexes, Ages ≥ 45 Years, N, Selected Years 2016-2026 42

List Of Figures, Charts and Diagrams in EpiCast Report: Heart Failure - Epidemiology Forecasts to 2026 [Report Updated: 12-06-2017]

1.2 List of Figures

- Figure 1: 7MM, Diagnosed Incident Cases of HF, Both Sexes, Ages ≥ 45 Years, 2016 and 2026 6
- Figure 2: 7MM, Diagnosed Prevalent Cases of CHF, Both Sexes, Ages ≥ 45 Years, 2016 and 2026 7
- Figure 3: 7MM, Age-Standardized Diagnosed Incidence of HF (Cases per 100,000 Population), Men and Women, Ages ≥ 45 Years, 2016 11
- Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of CHF (%), Men and Women, Ages ≥ 45 Years, 2016 12
- Figure 5: 7MM, Sources Used to Forecast Diagnosed Incident Cases of HF 14
- Figure 6: 7MM, Sources Used and Not Used to Forecast Diagnosed Prevalent Cases of CHF 15
- Figure 7: 7MM, Sources Used to Forecast Diagnosed Incident Cases of HF by EF 16
- Figure 8: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of CHF by EF 17
- Figure 9: 7MM, Sources Used to Forecast Diagnosed Incident Cases of HF by Ventricular Dysfunction 18
- Figure 10: 7MM, Sources Used to Forecast Hospitalizations for Acute HF 19
- Figure 11: 7MM, Sources Used to Forecast Hospitalizations for Acute HF by Worsening CHF, Advanced HF, and de novo 20
- Figure 12: 7MM, Sources Used to Forecast Hospital Length of Stay for Acute HF Hospitalization 21
- Figure 13: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of CHF by NYHA Class 22
- Figure 14: 7MM, Age-Specific Diagnosed Incident Cases of HF, Both Sexes, Ages ≥ 45 Years, N, 2016 35
- Figure 15: 7MM, Sex-Specific Diagnosed Incident Cases of HF, Ages ≥ 45 Years, N, 2016 36
- Figure 16: 7MM, Diagnosed Incident Cases of HF by EF, Both Sexes, Ages ≥ 45 Years, N, 2016 37
- Figure 17: 7MM, Diagnosed Incident Cases of HF by VD, Both Sexes, Ages ≥ 45 Years, N, 2016 38
- Figure 18: 7MM, Acute HF Hospitalizations, Both Sexes, Ages ≥ 45 Years, N, 2016 to 2026 39
- Figure 19: 7MM, Acute HF Hospitalizations by Patients Admitted and Discharged, Both Sexes, Ages ≥ 45 Years, 2016 39
- Figure 20: 7MM, Acute HF Hospitalizations by Worsening Chronic HF, Advanced HF, and De Novo HF, Both Sexes, Ages ≥ 45 40
- Figure 21: 7MM, Hospital Length of Stay for Acute HF Hospitalization, Both Sexes, Ages ≥ 45 Years, N, 2016 41
- Figure 22: 7MM, Age-Specific Diagnosed Prevalent Cases of CHF, Both Sexes, Ages ≥ 45 Years, N, 2016 42
- Figure 23: 7MM, Sex-Specific Diagnosed Prevalent Cases of CHF, Both Sexes, Ages ≥ 45 Years, N, 2016 43
- Figure 24: 7MM, Diagnosed Prevalent Cases of CHF by EF, Both Sexes, Ages ≥ 45 Years, N, 2016 44

Figure 25: 7MM, Diagnosed Prevalent Cases of CHF by NYHA Class, Both Sexes, Ages ≥ 45 Years, N, 2016 45

Figure 26: 7MM, Diagnosed Prevalent Cases of CHF with REF by NYHA Class, Both Sexes, Ages ≥ 45 Years, N, 2016 46

Figure 27: 7MM, Diagnosed Prevalent Cases of CHF with PEF by NYHA Class, Both Sexes, Ages ≥ 45 Years, N, 2016 47

How to Buy...

EpiCast Report: Heart Failure - Epidemiology Forecasts to 2026 [Report Updated: 12-06-2017]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/105615>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$3995** | Single User Price
- \$7990** | Site License Price
- \$11985** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.